Kenta Motomura

Iizuka, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Journal: Anticancer research
Published: May 28, 2026

Pretreatment Tumor-infiltrating CD8+ T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma.

Pretreatment Tumor-infiltrating CD8+ T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma.

Journal: Anticancer research
Published: April 05, 2026

Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation.

Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation.

Journal: Anticancer research
Published: February 02, 2026

Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab.

Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab.

Journal: Cancer diagnosis & prognosis
Published: January 24, 2026

Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab-Durvalumab.

Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab-Durvalumab.

Journal: Anticancer research
Published: September 12, 2025

Prediction of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy Using Agile 3+ and End-of-Treatment Alpha-Fetoprotein Levels in Patients With Hepatitis C.

Prediction of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy Using Agile 3+ and End-of-Treatment Alpha-Fetoprotein Levels in Patients With Hepatitis C.

Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: August 28, 2025

NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.

NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)
Published: August 21, 2025

Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study.

Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study.

Journal: Anticancer research
Published: June 30, 2025

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Journal: Nature communications
Published: May 28, 2025

A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma.

A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma.

Journal: Liver cancer
Published: April 21, 2025

Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma.

Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma.

Journal: Anticancer research
Published: February 27, 2025

Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice.

Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice.

Journal: Cancers
Published: November 25, 2024
Showing 1-12 of 54

Last Updated: 09/26/2026